MedWatch

Analyst: The sum is bigger than the individual parts for ALK

A possible approval of the vaccine, Mitizax, against house dust mite allergy, following presentation of positive data earlier in the week, could boost sales of another allergy product from ALK – the grass pollen allergy vaccine Grazax.

Foto: ALK / PR

ALK-Abello’s announcement earlier in the week concerning positive results for the Danish company’s vaccine against house dust mite allergy, Mitizax, was good news in itself, but there might be even more reason to rejoice following the news, says Sydbank-analyst Søren Løntoft Hansen.

“They already have Grazax on the European market, and there were very high expectations for sales of that drug which were never met, but if Mitizax hits the market ALK might have the missing piece enabling them to raise sales for Grazax as well. Because ALK has suffered from not being able to offer a broader palette of allergy vaccines to patients,” the analyst tells Medwatch, before elaborating:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Analytikere ser købere til GN men tvivler på et salg

Med en lav værdiansættelse, en høj strukturel værdi og ingen dominerende aktionærer giver det god mening, hvis internationale kapitalfonde og industrielle spillere lige nu lurer på at købe høre- og lydkoncernen GN Store Nord, mener to analytikere, men om det reelt kommer til at ske, tvivler de dog på.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier